Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.

10 Feb 2021

Novel immunotherapy approach to revert the main hallmarks of cat allergy

Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system's allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy.

5 Feb 2021

$FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma$

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

5 Feb 2021

FDA approves first injectable, complete regimen for HIV-1 infection in adults

The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

21 Jan 2021

ACAAI releases guidance related to risk of allergic reactions to Pfizer-BioNTech COVID-19 vaccine

With the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine by the FDA on December 11, 2020, and distribution beginning today, the American College of Allergy, Asthma and Immunology COVID-19 Vaccine Task Force recommends the following guidance related to risk of an allergic reaction on vaccination for those who receive the vaccine.

14 Dec 2020

Researchers reveal new mechanism of pain control

Researchers in Japan have revealed a previously unknown mechanism for pain control involving a newly identified group of cells in the spinal cord, offering a potential target for enhancing the therapeutic effect of drugs for chronic pain.

25 Nov 2020

Researchers use single-cell RNA sequence analysis to address the cornea's healing process

The insulation around nerve cell components in our corneas have unique properties, and little is known about them.

24 Nov 2020

FDA expands approved indication for influenza treatment to include post-exposure prevention

Today, the U.S. Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of age and older after contact with an individual who has the flu.

23 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

New therapeutic approach brings hope for treating psoriasis

Disruptive innovations in psoriasis are leading the way at EADV's 29th Congress, EADV Virtual. New data published today shows the first clinical evidence of modulating systemic inflammation by oral delivery of a non-living single strain commensal microbe.

29 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

Spider venom peptide could help stop pain in irritable bowel syndrome

Their study titled, "A spider-venom peptide with multi-target activity on sodium and calcium channels alleviates chronic visceral pain in a model of irritable bowel syndrome," is published in the latest issue of the journal Pain.

22 Sep 2020

Non-invasive test of brain function could predict treatment response in depressed teen girls

The risk of developing major depressive disorder (MDD) surges during adolescence-particularly for girls. Cognitive behavioral therapy (CBT) can be an effective treatment, but only about half of girls diagnosed with depression show significant improvement.

16 Sep 2020

Researchers discuss the role of chemical senses in disease and social interactions in humans, animals

Across 5 days in August (3rd-7th), scientists from around the world gathered virtually to present and discuss new information on the role of the chemical senses in disease, nutrition, and social interactions in humans and animals.

9 Sep 2020

Scientists identify genetic risk factors underlying penicillin allergy

Penicillin, a life-saving medicine, is the most common cause of drug allergy, with clinical manifestations ranging from temporary skin reactions to life-threatening systemic syndromes.

3 Sep 2020

Lysin-based antibacterial agent can help treat drug-resistant bacterial infections

The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of Methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States.

3 Sep 2020

Study shows how genetics could improve safety and efficacy of drugs for COVID-19 treatment

Over the past few months, a number of drugs have been under investigation to treat COVID-19 without well-established safety or data to support these claims.

28 Aug 2020

Vaping-related lung injuries have suggestive patterns on CT scans

Injuries to the lungs from vaping have suggestive patterns on CT scans that could help physicians make accurate diagnoses and reduce unnecessary biopsies, according to a new study published in the journal Radiology: Cardiothoracic Imaging.

27 Aug 2020

Researchers develop vaccine for human herpesvirus 6B

A research group led by Professor MORI Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B).

20 Aug 2020